PDCD1 and neoplasm: Recently, Chen et al12 demonstrated that CD38 upregulation in tumor induces resistance to programmed cell death 1 (PD‐1)/programmed cell death ligand 1 (PD‐L1) blocking antibodies and coinhibition of CD38 and PD‐L1 improves antitumor immune responses.